Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000

Core Insights - Nutriband Inc. has successfully exercised warrants at a strike price of $6.43, generating proceeds of $5,306,000 for the company [1][2] Financial Summary - The proceeds from the warrant exercise will primarily fund the remaining clinical development of AVERSA Fentanyl and the submission of its New Drug Application (NDA) to the FDA for marketing approval [2] - AVERSA Fentanyl is projected to achieve peak annual sales in the U.S. ranging from $80 million to $200 million [2] Product Development - Nutriband is focused on developing a portfolio of transdermal pharmaceutical products, with AVERSA Fentanyl being the lead product under development [2] - The AVERSA™ technology aims to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, and can be integrated into any transdermal patch [2]